Importance of inflammation in dry eye

Article

A more dynamic therapeutic approach is needed

According to Prof. Stefano Barabino (Clinica Oculistica, University of Genoa, Italy) our approach to dry eye must take into account the fact that it is an inflammatory disorder. In his presentation at the World Ophthalmology Congress in Abu Dhabi, United Arab Emirates, Prof. Barabino discussed the importance of inflammation in the treatment of dry eye.

"First of all," Prof. Barabino said, "when we are talking about dry eye we should keep in mind that we are dealing with the ocular surface." He went on to explain that the ocular surface comprises the tear film, lacrimal glands, corneal and conjunctival epithelia and the meibomian glands, which all work together to protect the ocular surface.

"However, is it dry eye if there is inflammation on the ocular surface," he questioned. "The majority of you will think the answer is yes... so why would you be correct?"

In 2005, Prof. Barabino and the team of Prof. Reza Dana conducted an investigation at the Schepens Eye Research Institute, Harvard University, Boston, USA, on mice in a controlled-environment chamber to determine what effect low-humidity and air flow would have on ocular surface signs.1 These mice developed dry eye to a statistically significant level when compared with a control group of mice. In particular, they demonstrated that fluorescein corneal staining was increased, and that surprisingly tear secretion was decreased after 7 days of exposure to the controlled environment. Also, based on the technique previously developed by the group, the cornea of mice was studied for immunological cells.

Prof. Barabino said, "We used specific markers for macrophages and dendritic cells in these mice corneas and we found that in the periphery and also the centre of the cornea, there is an increased number of these cells, which indicated the presence of an activation of immunological cells in the cornea in mice with dry eye disease."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.